Oseltamivir: A review of its use in influenza

Drugs

Volumn 61, Issue 2, 2001, Pages 263-283

  McClellan, K ^a   Perry, C M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; AMANTADINE; EN 241104; OSELTAMIVIR; PLACEBO; RIMANTADINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; BIOEQUIVALENCE; BRONCHITIS; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG TOLERABILITY; GASTROINTESTINAL ABSORPTION; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; NAUSEA; REVIEW; VERTIGO;

HUMAN INFLUENZA VIRUS; INFLUENZA VIRUS; INFLUENZAVIRUS A; INFLUENZAVIRUS B;

EID: 0035096415     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161020-00011     Document Type: Review

References (59)

1. Influenza
2. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
3. Costs and benefits of prevention and disease management
4. Influenza virus neuraminidase inhibitors
5. Development of antivirals against influenza
6. New approaches to influenza chemotherapy. Neuraminidase inhibitors
7. Approaches and strategies for the treatment of influenza virus infections
8. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers
9. Zanamivir: A review of its use in influenza
10. Oseltamivir
11. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection
12. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor
13. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized, controlled trials for prevention and treatment
14. Oral oseltamivir in human experimental influenza B infection
15. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial
16. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial
17. Oral oseltamivir reduces the duration of influenza illness by 2.7 days in previously healthy adults
18. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza
19. Influenza virus resistance to neuraminidase inhibitors
20. Influence of treatment schedule and viral challenge dose on the in vivo influenza virus-inhibitory effects of the orally administered neuraminidase inhibitor GS 4104
21. In vitro selection and characterization of a human influenza virus with decreased susceptibility to GS 4071
22. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071
23. Lack of in vivo development of influenza A virus resistance to the orally effective neuraminidase inhibitor GS4104
24. Phenotypic and genotypic assay of influenza virus neuraminiase indicates a low incidence of viral drug resistance during treatment with oseltamivir
25. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en
26. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en
27. Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice
28. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers
29. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802
30. Pharmacokinetics of the oral neuraminidase inhibitor oseltamivir in pediatric patients
31. The effect of food on the pharmacokinetics of the novel oral neuraminidase inhibitor RO 64-0796/GS4104
32. Oral oseltamivir rapidly delivers active drug levels to middle ear and sinuses in humans
33. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104
34. Distribution of the influenza neuraminidase inhibitor GS4071 in ferrets, following oral administration of its prodrug GS4104
35. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor Ro 64-0796 in subjects with renal impairment
36. The pharmacokinetics and safety of the oral neuraminidase inhibitor RO 64-0796/GS4104 when administered concurrently with cimetidine or probenecid in healthy subjects
37. The safety and pharmacokinetics of the neuraminidase inhbitor Ro 64-0796 when administered concurrently with paracetamol
38. Oral oseltamivir treatment of influenza in children
39. Oral oseltamivir is effective in the treatment of acute influenza in a vaccinated population
40. Treatment of influenza A and B lower respiratory tract infections with oseltamivir in solid organ and bone marrow transplant recipients
41. Long term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail elderly population
42. Effectiveness of oseltamivir in preventing influenza in household contacts: A randomised controlled trial
43. Maximising benefits of influenza treatment with oral oseltamivir: Results of the IM-PACT study
44. Impact of endpoint definition on efficacy in studies with oseltamivir
45. Oral oseltamivir reduces the risk of developing acute otitis media following influenza infection in children
46. Oral oseltamivir is effective in the treatment of acute influenza in a vaccinated population
47. The efficacy anad cost effectiveness of vaccination against influenza among elderly persons living in the community
48. Influenza vaccination programs for elderly persons: Cost-effectiveness in a health maintenance organization
49. Children with influenza A infection: Treatment with rimantadine
50. Recovery of drugresistant influenza A virus during therapeutic use of rimantadine
51. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families
52. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2)
53. Influenza - A new problem?
54. Antiviral agents for treating influenza
55. Managing influenza in primary care: A practical guide to clinical diagnosis